Robin Foà researcher
Foa, Robert
Foa, Robin
VIAF ID: 205289524 (Personal)
Permalink: http://viaf.org/viaf/205289524
Preferred Forms
- 100 1 0 ‡a Foa, Robert
-
- 100 1 _ ‡a Foa, Robert
- 100 1 _ ‡a Foa, Robin
- 100 0 _ ‡a Robin Foà ‡c researcher
4xx's: Alternate Name Forms (1)
Works
Title | Sources |
---|---|
Acute leukaemia an overwiew of new immunotherapeutic strategies | |
Increased chronic lymphocytic leukemia proliferation upon IgM stimulation is sustained by the upregulation of miR-132 and miR-212. | |
Increased serum BAFF (B-cell activating factor of the TNF family) level is a peculiar feature associated with familial chronic lymphocytic leukemia | |
Interleukin (IL)-3/granulocyte macrophage-colony stimulating factor/IL-5 receptor alpha and beta chains are preferentially expressed in acute myeloid leukaemias with mutated FMS-related tyrosine kinase 3 receptor. | |
Introducing biological features at diagnosis improves the relapse risk stratification in patients with acute promyelocytic leukemia treated with ATRA and chemotherapy. | |
Is now the time for molecular driven therapy for diffuse large B-cell lymphoma? | |
Late relapse of acute myeloid leukemia with mutated NPM1 after eight years: evidence of NPM1 mutation stability | |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma | |
Lessons for the clinic from rituximab pharmacokinetics and pharmacodynamics | |
Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia | |
The limit for chronic myeloid leukemia relapse after allogeneic hematopoietic stem cell transplant moves ever forward: when can you safely talk about healing? | |
Lineage switch from pro-B acute lymphoid leukemia to acute myeloid leukemia in a case with t(12;17)(p13;q11)/TAF15-ZNF384 rearrangement | |
Long-term results of high-dose imatinib in children and adolescents with chronic myeloid leukaemia in chronic phase: the Italian experience. | |
Longitudinal analysis of human herpesvirus-8 DNA and antibodies in an Italian allogeneic stem cell transplant recipient. | |
The lymphoid leukaemias, 1990: | |
M4 and M5 acute myeloid leukaemias display a high sensitivity to Bortezomib-mediated apoptosis | |
MACOP-B and involved-field radiotherapy is an effective and safe therapy for primary mediastinal large B cell lymphoma | |
A mammalian microRNA expression atlas based on small RNA library sequencing | |
Management of the 2009 A/H1N1 influenza pandemic in patients with hematologic diseases: a prospective experience at an Italian center | |
MEK blockade converts AML differentiating response to retinoids into extensive apoptosis | |
Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA--Italian Multiple Myeloma Network | |
Minimal residual disease monitoring in chronic lymphocytic leukaemia patients. A comparative analysis of flow cytometry and ASO IgH RQ-PCR. | |
Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia | |
Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma | |
Monoclonal B-cell lymphocytosis: a reappraisal of its clinical implications | |
Multiple distinct sets of stereotyped antigen receptors indicate a role for antigen in promoting chronic lymphocytic leukemia | |
Mutation of the receptor tyrosine phosphatase PTPRC | |
Negative prognostic value of CD34 antigen also if expressed on a small population of acute promyelocytic leukemia cells. | |
New therapies in onco-hematology and new infectious risk factors. | |
NOTCH1 mutations in +12 chronic lymphocytic leukemia (CLL) confer an unfavorable prognosis, induce a distinctive transcriptional profiling and refine the intermediate prognosis of +12 CLL | |
NOTCH1, SF3B1, BIRC3 and TP53 mutations in patients with chronic lymphocytic leukemia undergoing first-line treatment: correlation with biological parameters and response to treatment. | |
A novel point mutation within the juxtamembrane domain of the flt3 gene in acute myeloid leukemia. | |
The PAX5 gene is frequently rearranged in BCR-ABL1-positive acute lymphoblastic leukemia but is not associated with outcome. A report on behalf of the GIMEMA Acute Leukemia Working Party | |
Phenotypic and functional characterization of monocyte-derived dendritic cells in chronic lymphocytic leukaemia patients: influence of neoplastic CD19 cells in vivo and in vitro. | |
Philadelphia-positive acute lymphoblastic leukemia patients already harbor BCR-ABL kinase domain mutations at low levels at the time of diagnosis | |
Podocalyxin is expressed in normal and leukemic monocytes. | |
Posaconazole prophylaxis during front-line chemotherapy of acute myeloid leukemia: a single-center, real-life experience | |
Practical management of ibrutinib in the real life: Focus on atrial fibrillation and bleeding. | |
Primary mediastinal lymphoma: diagnosis and treatment options | |
Prognostic factors associated with a stable MR4.5 achievement in chronic myeloid leukemia patients treated with imatinib. | |
Prognostic significance of lymphocyte morphology in patients with advanced chronic lymphocytic leukemia treated with first line therapy of fludarabine + prednisone | |
The prognostic value of CD38 expression in chronic lymphocytic leukaemia patients studied prospectively at diagnosis: a single institute experience. | |
Prospective cytomegalovirus monitoring during first-line chemotherapy in patients with acute myeloid leukemia | |
Protein kinase gene expression profiling and in vitro functional experiments identify novel potential therapeutic targets in adult acute lymphoblastic leukemia | |
PTPN2 negatively regulates oncogenic JAK1 in T-cell acute lymphoblastic leukemia | |
Raising hematology's European voice: the importance of calling yourself a hematologist | |
Reappraising the timing of transplant for indolent non-Hodgkin lymphomas | |
Recurrent rearrangement of the Ewing's sarcoma gene, EWSR1, or its homologue, TAF15, with the transcription factor CIZ/NMP4 in acute leukemia | |
Resistance of acute myeloid leukemic cells to the triterpenoid CDDO-Imidazolide is associated with low caspase-8 and FADD levels | |
Resistance to CD95-mediated apoptosis of CD40-activated chronic lymphocytic leukemia B cells is not related to lack of DISC molecules expression. | |
Results of a multicenter, controlled, randomized clinical trial evaluating the combination of piperacillin/tazobactam and tigecycline in high-risk hematologic patients with cancer with febrile neutropenia. | |
Risk-adapted treatment of acute promyelocytic leukemia: results from the International Consortium for Childhood APL | |
Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience | |
RNA sequencing unravels the genetics of refractory/relapsed T-cell acute lymphoblastic leukemia. Prognostic and therapeutic implications | |
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study | |
Safety of obinutuzumab alone or combined with chemotherapy for previously untreated or relapsed/refractory chronic lymphocytic leukemia in the phase IIIb GREEN study | |
Saliva is a reliable and practical source of germline DNA for genome-wide studies in chronic lymphocytic leukemia. | |
Selective splenic artery embolization for the treatment of thrombocytopenia and hypersplenism in paroxysmal nocturnal hemoglobinuria | |
Simple genetic diagnosis of hairy cell leukemia by sensitive detection of the BRAF-V600E mutation. | |
Stage I/II follicular lymphoma: spread of bcl-2/IgH+ cells in blood and bone marrow from primary site of disease and possibility of clearance after involved field radiotherapy | |
Stereotyped subset #1 chronic lymphocytic leukemia: a direct link between B-cell receptor structure, function, and patients' prognosis. | |
Subnetwork-based analysis of chronic lymphocytic leukemia identifies pathways that associate with disease progression | |
Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia | |
Therapeutic potential of MEK inhibition in acute myelogenous leukemia: rationale for "vertical" and "lateral" combination strategies | |
Timing and deepness of response to tyrosine kinase inhibitors as a measure of potential treatment discontinuation in chronic myeloid leukemia patients managed in the real-life. | |
Total body computed tomography scan in the initial work-up of Binet stage A chronic lymphocytic leukemia patients: Results of the prospective, multicenter O-CLL1-GISL study | |
Towards an integrated classification of adult acute lymphoblastic leukemia | |
Treatment of 72 newly diagnosed Waldenstrom macroglobulinemia cases with oral melphalan, cyclophosphamide, and prednisone: results and cost analysis | |
Treatment of children with B-cell non-Hodgkin lymphoma in a low-income country | |
Trisomy 13 in a patient with common acute lymphoblastic leukemia: description of a case and review of the literature | |
Tumor evolutionary directed graphs and the history of chronic lymphocytic leukemia | |
Unrelated cord blood transplant in children with high-risk acute lymphoblastic leukemia: a long-term follow-up. | |
Unusual malignant tumours in 49 patients with HIV infection | |
The utility of a prognostic index for predicting time to first treatment in early chronic lymphocytic leukemia: the GIMEMA experience | |
Venetoclax: a chance for patients with chronic lymphocytic leukaemia previously treated with ibrutinib. | |
White blood cell count at diagnosis and immunoglobulin variable region gene mutations are independent predictors of treatment-free survival in young patients with stage A chronic lymphocytic leukemia |